Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| 56.55 | |
| 56.61 | |
| - | |
| 56.64 | |
| 56.52 | |
| 19.345-62.08 | |
| 2 843 M | |
| 50 225 K | |
| 0 | |
| -0.91 | |
| 1.491 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Billion-dollar companies are some of the most valuable companies. They lead the stock market and have become an integral part of the economy. Once, such companies were a rarity, but today there are ma...
The best way to get rich is not through get-rich quick schemes — slow and steady wins the race. It is not something to achieve in a single quarter or even a year. You create financial freedom that y...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
